CD20<sup>+</sup>多发性骨髓瘤的临床特点和治疗研究

刘圆圆; 朱明霞; 王晶; 包芳; 景红梅

doi:10.3971/j.issn.1000-8578.2017.01.007

CD20⁺多发性骨髓瘤的临床特点和治疗研究

Clinical Characteristics and Treatment of Multiple Myeloma with Positive Expression of CD20

摘要

摘要:
目的探讨CD20⁺多发性骨髓瘤的发病情况、临床特点及治疗选择。
方法回顾性分析2012年1月至2014年12月在北京大学第三医院确诊的CD20⁺多发性骨髓瘤患者资料。
结果共确诊143例多发性骨髓瘤患者，其中CD20阳性者12例，占同期骨髓瘤患者的8.4%；12例CD20阳性患者的中位发病年龄为55.5（40~81）岁，骨髓瘤细胞表面均表达CD20，但CD20的表达强度不同，仅有CD20^dim表达4例，CD20^bright表达2例；6例同时存在CD20^bright和CD20^dim的表达，其中4例CD20^dim的比例高，2例CD20^bright的比例高。12例患者中位生存时间22（1~40）月，其中3例获得CR，4例进展较快，在14月内死亡，1年总体生存率为83.3%。
结论 CD20⁺骨髓瘤患者的疾病过程具有多发性骨髓瘤的特点，部分患者经过治疗可以获得缓解；也有部分患者进展较快，而CD20的表达提供了一种可能的治疗选择。

Abstract:
Objective To analyze the clinical manifestations, diagnosis, therapy and prognosis of CD20⁺ multiple myeloma.
Methods From Jan 1, 2012 to Dec 31, 2014, there were 143 patients were diagnosed with multiple myeloma altogether, among them 8.4% (12/143) patients with CD20 positive expression.
Results The median age is 55.5(40-81) years old. Among the 12 patients with CD20 positive expression, 33.3%(4/12) cases were CD20^dim only whereas 16.7%(2/12) were CD20^bright only. The other 6 cases were positive with both CD20^bright and CD20^dim, 4 cases had more percentage of CD20^dim and 2 cases had more percentage of CD20^bright. Among 12 cases, median survival time was 22(1-40) months, 3 patients achieved CR and 4 patients were dead, 1-year overall survival was 83.3%.
Conclusion The clinical course of CD20⁺ multiple myeloma was typically similar with multiple myeloma, after treatment some can acquire complete remission, but some patients got rapid progress of the disease.

HTML全文

参考文献(19)

施引文献

资源附件(0)

CD20+多发性骨髓瘤的临床特点和治疗研究

Clinical Characteristics and Treatment of Multiple Myeloma with Positive Expression of CD20

CD20⁺多发性骨髓瘤的临床特点和治疗研究